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Yale has been fortunate indeed to havehad Dorothy Horstmann as amember of
its faculty for all but one ofthe last 50 years. Ithas had also the wisdom to take
cognizance ofher value as an individual and ofher contributions to biomedical
science and human welfare on two occasions in recent years. Her studies of
poliomyelitis, hepatitis, and rubella, executed with perceptiveness, rigor and
modesty, have benefited countless numbers; and for her many achievements all
are in her debt. I am beholden to her colleagues for this opportunity to pay trib-
ute to a wise and gracious friend.
Incasting about for a subjectbefitting this occasion, the thoughtoccurred that it
might be of interest to examine the contributions of some former and present
members of YAle's faculty to the subject of a group of infections still endemic
in all human societies, narnely those caused by Streptococcus pneumnoniae or
the pneumococcus. The list is doubtless not exhaustive but includes such nota-
bles as Wintemitz, Blake, Paul, Trask, Eaton, and Beeson of former days, as
well as reflecting ongoing investigations today by Eugene Shapiro and his col-
leagues. In reviewing some ofthis earlier work, it will be my endeavor to place
it in the context of contemporary understanding. In the interest of some sem-
blance of order, the material will be examined in topical rather than in chrono-
logical order, dealing with bacteriologic and immunologic, pathogenetic, thera-
peutic, andprophylactic considerations in thatsequence.
Pneumococci were first isolated independently from human carriers ofthe organism
in 1880 by Stemnberg and by Pasteur [1]. Their role as a major incitant ofbacterial pneu-
monia in man was demonstrated by Weichselbaum in 1886 [2]. Evidence of the hetero-
geneity ofpneumococcal strains began to appear at the end of the 19th century and was
established clearly by mouse protection tests reported by Neufeld and Handel in 1910.
One of the curious paradoxes of bacteriologic history is that the Quellung reaction, dis-
covered eight years earlier by Neufeld, was used neither by him nor by others in the next
two decades [3]. All the work until the 1930's done to delineate the first29 pneumococcal
types was carried out with other immunologic techniques, such as mouse protection,
agglutination, andprecipitin tests.
One of the most memorable members of Yale's medical faculty who had a life-long
interest in the pneumococcus and the infections it causes was Francis Gilman Blake [4].
Born in Pennsylvania in 1887, he grew up in New England, attended Dartmouth College,
and received his M.D. degree from Harvard in 1913. After house officer training at the
Peter Bent Brigham Hospital, Dr. Blake began his academic career as an assistant profes-
sor ofmedicine at the University of Minnesota in 1917, and that same yearpublished the
first of many papers dealing with the pneumococcus, one entitled "Methods for the
Determination ofPneumococcus Types" [5]. At thetime only three types had been delin-
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eated clearly, types 1, 2, and 3, but differences in prognosis among infections caused by
the three types had been recognized, and their identification was essential if serum for
therapy was to be employed. Blake discusses the importance of the proper collection of
sputum and its microscopic examination, both still relevant today, the intraperitoneal
inoculation of sputum into the mouse, and the employment ofperitoneal washings from
the mouse in agglutination and precipitin tests with type specific antisera, prepared
apparently at the Hospital of the Rockefeller Institute. Use of the latter test took cog-
nizance of the specific soluble substance of pneumococcus described by Dochez and
Avery in March, 1917. The precipitin reaction had the advantage ofproviding a specific
result when the presence of mixed bacterial flora in mouse peritoneal washings rendered
agglutination unfeasible. It was not until 1933 thatNeufeld and his collaborator, Etinger-
Tulczynska, reported using the Quellung reaction to type pneumococci. Its use in this
country followed publication in 1933 of a paper by Albert Sabin, who had learned the
technique from Kenneth Goodner following the latter's visit to Neufeld's Laboratory [3].
The Quellung testbecame the standard method for typing pneumococci in diagnostic lab-
oratories during the briefremaining period of serum therapy but is one employed rarely
in hospitals today. It has been resurrected of late in sentinel laboratories in several parts
of the world to ensure the appropriateness of the formulation of contemporary pneumo-
coccal vaccines.
Blake published a second report on immunologic aspects ofpneumococcal infection
the following year entitled "Antigen-Antibody Balance in LobarPneumonia" [6].
Aware ofthe studies ofDochez and Avery that a "soluble pneumococcus substance"
is present in the blood of some patients with severe lobar pneumonia and is excreted in
the urine ofa considerable number ofcases, Blake set out to determine the relationships
of this antigen to the earlier described antibody and whether or not these relationships
might be of prognostic value. He was able to categorize three groups of cases: (1) mild
infections with recovery and soluble pneumococcus substance undetectable in blood or
urine, (2) severe cases with bacteremia and soluble substance in urine but not blood
which recovered, and (3) fatal cases with bacteremia and increasing amounts of soluble
substance inboth blood and urine. Agglutinins appeared in the blood ofpatients in Group
1 usually about the timeofcrisis but were absent from theblood ofpatients in Group 3.
In the course of redeveloping pneumococcal vaccine, the immunologic phenomena
occurring in the course of bacteremic infection were reexamined quantitatively in the
1970s by means ofa radioimmunoassay [7]. The levels ofantibodies in apatientrecover-
ing from bacteremic type 4 pneumococcal pneumonia rose sharply in the month follow-
ing onset of infection, then fell to approximately half their peak value over the next six
months where they remained over the course of the next three years. Pneumococcal cap-
sular polysaccharides appear not to be degradable by mammalian enzymes and may be
detected by the use of immunofluorescent antibodies in the lymph nodes months after
their injection into experimental animals [8]. Both findings are consistent with the obser-
vation that recurrent infection of man with the same pneumococcal capsular we occurs
rarely, if ever, save in the agammaglobulinemic or dysgammaglobulinemic patient. The
radioimmunoassay can be used also to demonstrate the presence of circulating capsular
polysaccharide in patients with bacteremic pneumococcal pneumonia. Finally, one can
show with a modification of the same technique the occurrence of circulating antigen-
antibody complexes. An occasional patient with bacteremic pneumococcal pneumonia
will have at the onset of infection a small but measurable quantity of antibody to the
infecting pneumococcal type which declines steadily in amount during the early days of
illness at which time no free antigen is detectable. If the patient's serum is treated with a
proteolytic enzyme and reassayed for capsular antigen, the latter can then be identified.
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As shown by Frisch et al. [9] in the 1940's, the amount of pneumococcal capsular
polysaccharide present in the consolidated lung ofthe patient with lobarpneumonia may
exceed a gram in amount. Although the preponderance is doubtless expectorated during
recovery, itis notsurprising thatcapsular polysaccharide should be detectable in the urine
for a month or more afterrecovery.
Paul B. Beeson, who succeeded Blake as Chairman of the Department of Medicine
in 1952, a post which he held until departing for Oxford in 1965 to become the Nuffield
Professor ofMedicine [101, was occupied fora time with some immunological aspects of
pneumococcal infection in collaboration with Colin M. MacLeod, Charles L. Hoagland,
and Walther F. Goebel during his tenure at the Rockefeller Institute. His initial publica-
tion concerned use ofthe Francis test, the intradermal injection ofpneumococcal capsular
polysaccharide, to monitor the adequacy ofserum therapy oflobarpneumonia with either
horse or rabbit antisera and highlighted several factors ofcritical importance to its proper
interpretation [11]. In a similar vein, the utility ofintravenous calcium chloride in arrest-
ing chills inducedby antipneumococcal sera in treatingpneumonia was reported [12].
Beeson's major contribution concerned the immunological relationship between the
capsularpolysaccharide ofpneumococcus type 14 and the blood group A substance [13].
Earlier, Finland, and Curnan had reported from Boston on the severe reactions,
hemoglobinuria, and occasional deaths following the administration oftype 14 antipneu-
mococcal horse, but not rabbit, antiserum. With Goebel, Beeson had observed also that
human erythrocytes of all four blood groups were agglutinated to high titre by type 14
antipneumococcal horse sera, that absorption of the sera with human erythrocytes
removed the agglutinins as did absorption with type 14 capsular polysaccharide but that
absorption with the former did not significantly alter the titre of agglutinins of type 14
pneumococci. The phenomena were associated uniquely with equine antisera to this
pneumococcal type.
Purified preparations of the capsular polysaccharide of pneumococcus type 14 were
made and shown to consist of acetylglucosamine and galactose, major constituents of
blood group A substance. Absorption of type 14 antipneumococcal horse serum with
blood Group A substance removed approximately half the antibody nitrogen precipitable
by type 14 polysaccharide [14].
The therapeutic problem posed by the use of type 14 antipneumococcal horse serum
could be obviated by the use of antiserum prepared in rabbits in its stead. Differences in
the specificities of antibodies of these two species were demonstrated further by Beeson
and Goebel in a study of the cross reactivity oftheirrespective antibodies to pneumococ-
cus type 2 with Type B Friedlinder bacillus, classified today as Klebsiella pneumoniae
tywe 2 [15]. It had been reported earlier by Avery, Heidelberger, and Goebel that a cross
reaction could be demonstrated between the capsular antigens of these two organisms.
When the serologic reactions of rabbit and equine antibodies to pneumococcus type 2
with Type B Friedlander bacillus were examined, it was found that rabbit antibodies,
unlike those from the horse, failed to give a Quellung reaction with Type B Friedlinder
bacillus, to precipitate its capsular polysaccharide or to protect mice against lethal infec-
tion. These observations were congruent with the earlier ones demonstrating the greater
specificity of rabbit type 14 antipneumococcal serum, which, unlike horse antiserum to
the same pneumococcal type, failed to cross-react significantly with human blood group
substances.
A briefrevival ofinterest in these observations occurred about a decade ago after the
relicensure ofpolyvalent pneumococcal vaccine which included for the first time the cap-
sularantigen ofpneumococcus type 14 [16]. When it was discovered that somerecipients
of the vaccine were experiencing a rise in their blood group A isoagglutinins, the finding
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was thought initially by some to be attributable to the type 14 capsular polysaccharide in
the vaccine. It was shown subsequently, however, that the serologic findings were associ-
ated with vaccine prepared from pneumococci grown in a meat-based medium and that
the problem could be obviated by substituting a medium of plant-based origin. These
findings are consistent also with the fact that type 14 pneumococcal infection in man is
not associated with hemolytic phenomena.
Studies of the bacteriologic properties of pneumococci were carried out by several
investigators whose careers found them at one time oranother on the faculty at Yale. One
of them was John Rodman Paul [17]. Paul, who spent the greater part of his career at
Yale, had encountered at an earlier time several men who were later to be his colleagues.
As a child in Philadelphia, he had played with Stanhope Bayne-Jones, who was subse-
quently to instruct him in bacteriology at the Johns Hopkins University School of
Medicine and "to demonstrate the recent discovery that the family ofpneumococci could
be divided into 'three' types on the basis of agglutinin reactions," all this many years
before Bayne-Jones became Dean of Yale University School of Medicine [18]. Milton
Winternitz, of whom more anon, "taught (pathology) by the method of terrorism: 'no
knowledge without tears.' " Dr. Paul was to remark wryly at a later time that today it
would "almost seem that it is the professor who experiences terrorism." Paul's medical
education was interrupted by service with the Hopkins' base hospital in France during
World War I, and he received his medical degree in 1919. After two years ofinternship at
the Pennsylvania Hospital, he was named director of the Ayer Clinical Laboratory at that
institution.
In the 1920s and 1930s, there was considerable interest in colonial variation ofbac-
terial species infecting man. Noncapsulated pneumococci bad been isolated by Laura
Stryker oftheRockefeller Institute in thepreceding decade, and theattributes ofthe cells
and colonies of so-called smooth virulent capsulated and rough avirulent noncapsulated
variants of this species had been the object ofconsiderable scrutiny. Paul published four
papers on this topic, two in 1927 from Philadelphia [19-20] and two in 1934 subsequent
to his coming to Yale [21-22]. Others of the Yale faculty who investigated variation in
pneumococcal colonial morphology included Blake and James D. Trask [23], and
Monroe D. Eaton [24-25], the last known best for his later work on mycoplasmas.
At that time, "smoothness" of bacterial colonies was associated with virulence in a
number of species and "roughness" with the lack thereof. The use of these terms some-
times took a bizarre twist, as in the case ofBacillus anthracis, of which rough colonial
forms were referred to as "S" variants because of their attribute of virulence. The prob-
lem was one with which I became involved somewhat later. In an attempt to obtain non-
capsulated variants of pneumococci without having to make and employ anticapsular
serum, a possibility suggested by some reported studies of group B streptococci [26],
capsulated pneumococci were grown as widely separated colonies on sealed blood agar
plates incubated for 10 to 14 days [27]. Excrescences at the margins of such colonies
were distinctly rough in appearance and were thought initially to represent noncapsulated
variants. A Quellung test with homotypic anticapsular serum, however, showed these
so-called "rough" colonial variants to be composed of fully capsulated cells growing in
long chains or filaments. Ifthe inoculum employed in the initial experiment was replaced
by a noncapsulated diplococcal variant, the colonial excrescence in this instance would
be composed of noncapsulated cells growing in long chains or filaments. From these
experiments, it would seem reasonable to conclude that it is more informative to look at
bacterial cellular attributes than colonial ones. Studies of phagocytosis in vitro and of
mouse virulence show clearly the survival value ofthe nonfilamentous variants over that
ofthe filamentous ones.
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Paul sought, both at the AyerClinical Laboratory [20] and at Yale [22], to determine
if R or noncapsulated pneumococci could be identified as a component of the human
upper respiratory flora. The taxonomic separation of pneumococci from other alpha
hemolytic streptococci is a difficult one though it may be nearing resolution. The overall
base pair composition of the DNA ofpneumococci and some alpha streptococci is very
similar, being composed of 38 mol percent guanine plus cytosine. DNA-mediated inter-
specific transformation between organisms of the two groups may be carried out with
either serving as donor or recipient of streptomycin resistance. Many non-pneumococcal
streptococci are capsulated, and their capsular polysaccharides may be very similar to
those ofsomepneumococcal types. Antibodies to these alpha streptococci may be protec-
tive against infection with cross-reactive pneumococcal serotypes and may play a role in
so-called "natural" immunity [28]. Noncapsulated pneumococci instilled into the human
nose can be recovered from the upper respiratory tract as long as two weeks after their
placement there, butitremains an unanswered question whetheror not such variants ever
comprise acomponentofthenormal human upperrespiratory flora.
Two notable members of Yale's medical faculty carried out extensive studies of the
pathogenesis of pneumococcal pneumonia: Milton C. Winternitz, who became Dean of
the School ofMedicine in 1920 and is credited with its renaissance, andFrancis G. Blake,
the other investigator of this problem, chosen by Winternitz to be chairman of the
Department ofMedicine.
Winternitz was born in Baltimore in 1885 and attended medical school at Johns
Hopkins at the same time as my father. A colorful account of his role as a teacher of
pathology is given by John R. Paul in volume 43 of The Yale Journal ofBiology and
Medicine [29]. Winternitz published a series ofnine papers with several collaborators on
the pathogenesis of pneumococcal pneumonia in The Journal ofExperimental Medicine
between 1913 and 1915, which, together, provide ample evidence of his ability as an
experimentalist [30-38]. These studies, in which pneumonia was induced by inoculation
through an intratracheal catheterofan untyped pneumococcus obtained from thebloodof
a human patient, were carried out both in normal rabbits and in animals rendered agranu-
locytic with benzol. They give insights into the susceptibility of the mammalian lung to
infection, the role ofpolymorphonuclear leukocytes in defense against infection and the
failure of trypanocidal dyes to affect the pneumococcus. Among the more ingenious and
intriguing ofthese investigations are the studies ofintra vitam staining ofthe lung andits
vasculature in experimental pneumonia [37]. When one percent trypan blue was injected
intravenously into a rabbit prior to pneumococcal infection of the lung, the pneumonic
area was stained uniformly, especially the fibrinous exudate. Many leukocytes failed to
take up the dye, however, indicative of the fact that they were still viable. If, however,
injection ofthe dye was delayed until 20 to 65 hrs afterinfection ofthe lung,paleconsol-
idated areas were present in the involved lobes resembling wedge-shaped infarcts. The
prevailing view at the time was that pallor of the affected lung was the resultofcapillary
compression by the alveolar exudate. To test this hypothesis, pneumonic lungs of both
humans and rabbits were injected through the pulmonary artery with a Berlin blue gelatin
solution under a pressure of 120 mm Hg, the pulmonary artery tied and the lungs fixed.
On sectioning, the consolidated areas were pale gray, the unaffected areas of the lung
intensely blue; and, on microscopic examination, the consolidated areas were remarkable
for the absence ofdye from the capillaries. When one lung ofa normal pair was hyperin-
flated and the pulmonary artery injected with dye as before, there was no difference in the
amount ofdye in the alveolarcapillaries ofthe two lungs. Even when one lung was filled
through the bronchus with dye solution at a pressure of 120 mm Hg, there was no differ-
ence in the vessels of the two lungs after perfusion of the pulmonary artery. Neither did
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rendering the animals leukopenic with benzol alter the distribution of intravenously
injected dye. In the leukopenic rabbit, the exudate consisted almost entirely of fibrin. To
inhibit the formation offibrin, animals were injected subcutaneously with an old solution
ofphosphorus in olive oil andgiven a small amount ofchloroform in 30% alcohol intra-
gastrically. In 24 hrs,clotting was observed to be delayed and the clotjelly-like. Such an
animal inoculated intrabronchially with a pneumococcal culture died in 17 1/2 hrs with
consolidation of the left lower lobe. The lungs were injected through the pulmonary
artery as before, the lungs fixed and sectioned. The consolidated area on this occasion
wasuniformly blue and its vessels contained dye. The fibrin plugs found in areas of con-
solidation of normal animals were absent. It was hypothesized by the investigators in
these ingenious experiments that the absence ofantitryptic substance in serum secondary
to impairment of capillary circulation in the normal animal favored resolution of the
pneumonic lesionby the uninhibited action ofleukocytic enzymes in the pneumonic exu-
date. Their observations are consistent also with the now accepted concept that cyanosis
inpneumonia is not the result ofblood circulating through unaerated lung, but rather the
consequence ofimpaired alveolar ventilation secondary torapidshallow breathing.
Five years later, a second series of investigations of experimental pneumococcal
pneumonia, this time in primates, was reported by Francis G. Blake and Russel L. Cecil
in The Journal ofExperimental Medicine [39-45]. The investigations, carried out at the
Bacteriological Laboratory of the Army Medical School in Washington, were prompted
by the military experience with influenza and pneumonia during the pandemic of
1918-1919. Disease wasproduced in Philippine macaques and Central American Cebus
monkeys by injecting an inoculum of pneumococci into the trachea through a needle
inserted between the tracheal cartilages. In their initial report, Blake and Cecil concluded
that thepneumococcus is thespecific cause of lobarpneumonia, that neither colonization
oftheupperrespiratory tract nor intravenous injection ofpneumococci gave rise to pneu-
monia but thatpneumonia is bronchogenic in origin and that bacteremia is secondary to
invasion of the lungs.
Blake and Cecil's observations on thepathology and pathogenesis of pneumococcal
pneumonia, however, seem somewhat at variance with contemporary views on these sub-
jects [40]. It was their conclusion that thepneumococcus invades the tissue of the lung at
somepoint near the root of the affected lobe and spreads peripherally via the interstitium
and lymphatics of the organ; i.e., that lobar pneumonia is primarily an interstitial infec-
tion. Winternitz was aware of these studies from oral presentations of their findings by
Blake and Cecil before several societies in 1919. In a report published in 1920 in the
Bulletin of the Johns Hopkins Hospital entitled "An Unrecognized Pathway for Bacterial
Invasion of the Lower Respiratory Tract," Winternitz described the extensive plexus of
lymphatic vessels underlying the tracheal mucosa which drained downward to the hilum
of the lung to involve the bronchial, pleural, and mediastinal lymphatics [46]. The with-
drawal ofan infected needle through the trachealwall gave rise to a descending infection
in the rabbit with striking resemblance to the findings ofBlake and Cecil. Infection of the
lung through a tracheobronchial catheter, on the other hand, successfully introduced to
avoid mucosal trauma, gave rise to apneumonitis characterized by spread through the air-
ways as is accepted generally today. The story is adramatic example of how an experi-
mental detail can alter the outcome ofan investigation.
The collaborators at the Army Medical School went on to describe spontaneous
pneumococcal pneumonia in monkeys [41], the protective effect of recovery from sub-
lethal infection against reinfection with the samepneumococcal type [44], and the thera-
peutic effect ofpassively administered typespecific antipneumococcal serum prepared by
theNew York State Board ofHealth, presumably in horses [45].
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Dr. Blake maintained a lifelong interest in pneumococcal pneumonia and its treat-
ment and published on each of the therapeutic advances as sulfonamides largely replaced
antiserum, and penicillin, in turn, replaced sulfonamides [47]. One of the therapeutic
approaches explored in the 1930's and now largely forgotten, was the use ofpneumotho-
rax. Between 1934 and 1940. Blake published six articles on the subject including a
lengthy review in thejournal Medicine [48]. The investigation was inspired by the publi-
cation of Lt. Rood, Medical Corps, U.S. Army, in 1919 of the results of pneumothorax
occurring as a sequel todiagnostic lung puncture: "It was interesting to note thatoften the
patient was relievedby lung puncture, especially ifpneumothorax followed the operation,
and it was not uncommon for patients to request that the operation be repeated. Patients
frequently showed a drop in temperature following puncture and a temporary improve-
ment in physical signs. The cough and sputum would increase for a short time, followed
by a marked decrease in the number ofrales within a few hours." After extensive investi-
gation, Blake concluded in 1938: "Artificial pneumothorax would appear to be of value
for the relief of pleural pain in selected early cases of lobar pneumonia. It has not been
demonstrated that it possesses any curative value in this disease" [49]. The introduction
ofpenicillin for the treatment ofpneumococcal pneumonia in 1944 was to make all such
therapies obsolete.
Cecil and Blake were stimulated by the epidemics ofrespiratory disease in 1918 and
1919 to investigate also the efficacy of prophylactic vaccination against pneumococcal
pneumonia in the monkey. Large scale trials of vaccines of whole killed pneumococcal
cells in man hadbeen initiated in South Africa in 1911 by SirAlmroth Wrightandcontin-
ued by his prot6g6, F. Spencer Lister, with inconclusive results [50]. Similar trials of two
trivalent vaccines were conducted in this country by Cecil in 1918, one atCamp Upton in
New York in collaboration with J. Harold Austin [51], who like a former member of the
Yale medical faculty, William Stadie, was an illustrious predecessor of mine in the
Department ofResearch Medicine at the University ofPennsylvania. The other trial was
carried out at Camp Wheeler in Georgia [52]. Both trials, each including more than
10,000 recipients ofvaccine, were suggestive of the prophylactic value ofvaccination in
reducing the incidence ofpneumococcal pneumonia. Careful analysis ofthe data, howev-
er, failed to establish unequivocally such a conclusion. To study further the question of
active immunity, Cecil and Blake undertook, therefore, a series ofinvestigations in mon-
keys.
For their source ofvaccine, Cecil and Blake chose the type 1 strain ofpneumococcus
included in the military vaccines, one of greatly reduced virulence that might well be
classified today as an intermediate capsular variant producing small amounts ofcapsular
polysaccharide [42]. Variants of this kind, as has been learned subsequently, may arise
from mutations in any ofthe several genes in the multigenic pathway controlling the syn-
thesis of the pneumococcal capsule [53]. As had been the case in the two military trials,
two types of vaccine, one a saline suspension of heat-killed organisms, the other a "lipo-
vaccine" consisting ofthe ground sediment ofheat-killed organisms suspended in cotton-
seed oil, were employed, Although the number of pneumococcal organisms injected in
each of the several experiments is known, the amount of type 1 capsular polysaccharide
cannotbe calculated and equated with that in other vaccines.
Monkeys receiving either vaccine were challenged by intratracheal inoculation with
a highly virulent type 1 pneumococcal strain or by exposure to a cage mate suffering
from type 1 pneumococcal pneumonia. Neither vaccine prevented infection in the inocu-
lated animals although the degree of bacteremia in the vaccinated animals was less than
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that in their unvaccinated counterparts. The reasons for the failure of the vaccines may
have been several. First, it is not clear than a sufficient amount of type 1 pneumococcal
capsular polysaccharide had been injected to induce immunity and second, in those ani-
mals challenged by intratracheal inoculation, the challenge may havebeen excessive.
In addition to the studies with killed vaccines, the immunity resulting from subcuta-
neous vaccination with living cultures ofpneumococci wasexplored [43]. Both a virulent
and the previously studied avirulent type 1 pneumococcal strain were employed. Two of
those animals surviving vaccination with the live virulent strain proved immune to chal-
lenge. Studies of the live aviruent pneumococcal vaccine were limited to two vaccinated
animals and one control. The authors concluded that: "Living avirulent pneumococci,
when injected subcutaneously, appear to excite an immunity equal in degree to that pro-
duced by living virulentpneumococci, ifa large enough dose is given."
In all their studies ofimmunization with killed and with livepneumococcal vaccines,
24 animals were vaccinated and 14 served as controls. When the various protocols are
taken also into account, the biostatistical probabilities of the results observed not having
occurred by chance would almost certainly fail to meet contemporary criteria of accept-
ability. Although biostatistical analysis had been advocated in 1913 by MajorGreenwood
in his caustic assessment ofSir Almroth Wright's pneumococcal vaccine trials published
in Lancet [54], the application of such methods had not yet achieved the wide use they
enjoy today.
Three years after Blake and Cecil published their studies ofpneumococcal infection
in monkeys, Schiemann and Casperreported the antigenicity ofa pneumococcal capsular
polysaccharide in mice [55], and, 22 years after theirreport, MacLeod and his coworkers
demonstrated, in an elegantly structured and controlled trial, that as little as 50 pg of a
purified pneumococcal capsular polysaccharide injected into man could effectively pre-
vent infection with the homotypic organism [56]. Space does not permit a recounting of
subsequent events in the history of pneumococcal vaccines which are reviewed else-
where. Suffice it to say that relicensure of such a vaccine in 1977 and release of an
expanded formulation of the vaccine in 1983 have not been unattended by controversy
[57]. One reason is the failure of some to take into account the inability ofthe aggregate
efficacy ofa vaccine designed to prevent 23 immunologically distinct infections to equal
that of a monovalent vaccine, which clearly it cannot. Others arise from recommenda-
tions that the vaccine be administered to immunocompromised patients incapable of
responding to the antigenic stimulus of the vaccine without stressing adequately the like-
lihood ofits failure in some such patients. Studies atYale by Eugene D. Shapiro,John D.
Clemens, and their associates have been major contributions to a better understanding of
the vaccine's role [58-59], one which may become ofincreasing importance as mounting
numbers ofpneumococci manifesting resistance to multiple antimicrobial drugs are iso-
lated from infected humans. Unanswered questions remain concerning the need or lack
thereoftorevaccinate and the wisdom ofdelaying vaccination until the seventh decadeof
life as is now recommended. It is gratifying to know that interest in the pneumococcus
persists atYale. Itbodes well forall.
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